Although gene therapy has been in discussion for decades, its translation to clinical practice has been a slow and challenging process. As a solution to this translational challenge, Allen et al. have proposed a peptide-based delivery method of Cre recombinase for in vivo gene therapy, which we review in this blog post.
In this webinar, Dr. Ejvind Mørtz discusses the benefits and applications of mass spectrometry (MS)-based host cell protein (HCP) analysis and why HCP ELISAs are insufficient for documenting product-related impurities. Watch to learn where to apply the assay in a typical process and what you gain from deploying it to your workflow.